Robert W. Franz Cancer Research Center
Forms & Information
Technology opens new doors for combining radiation and immunotherapy.
Learn clinical best practices and the latest advances in techniques, treatments, technology and research. Newsletter articles are reviewed by physician editorial boards and are written by Providence specialists in brain, spine, cancer, orthopedics, and heart and vascular medicine.
The Earle A. Chiles Research Institute offers a summer research program for undergraduate students who are seriously considering a career in biomedical sciences. The program offers direct hands-on research experience in one of the EACRI research laboratories.
Prostate cancer, once it spreads to lymph nodes and bones, generally is not curable. But basic and clinical researchers at Providence are working on this challenge.
From the experts
As knowledge about the immune system explodes, so does the potential of innovative treatments. – By Brendan Curti, M.D., medical director, Providence Genitourinary Oncology Research
Lymphedema may affect up to 60 percent of women after breast cancer treatment. This abnormal accumulation of fluid, or “edema,” is caused by a blockage of the lymphatic system. Often first noticed as a swelling, heaviness or tightness in the arm, hand, wrist, fingers, breast or torso on the same side as the affected breast, it can happen right after surgery or radiation, or years later.
Q. I recently had a benign breast lump removed. It turned out to be a “fibroadenoma,” and my doctor said it was totally benign. Still, I’m worried – does this mean I’m at an increased risk of breast cancer?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q: How long does it take for breast cancer to grow? My doctor just examined my breasts a month ago (no lumps), and today I found a lump. Is it possible that breast cancer could have developed so quickly?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q. I didn’t realize until recently that men can also get breast cancer. How common is it? If the women in my family have a history of breast cancer, should I be concerned?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q. I’m a young woman who tries to do breast self exams (BSE's) every month. But I often put them off because they make me so nervous. I just heard that not all health care organizations recommend monthly BSE's. What do you say?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q. I've just been diagnosed with ductal carcinoma in situ (DCIS.) I've heard it described as "stage 0" breast cancer. What does that mean? How worried should I be?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q. I am a breast cancer survivor. Is it safe for me to take hormone replacement therapy (HRT)?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center at Providence Portland Medical Center:
Q: What can you tell me about Arimidex vs. tamoxifen? Should a person on tamoxifen switch to Arimidex? And is there any benefit to taking Arimidex after five years on tamoxifen?
Answer from the expert staff of breast cancer research at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center:
Once again, tobacco use is firmly established as a cause of cancer, this time, colorectal cancer. – By Todd S. Crocenzi, medical oncologist and researcher
Answers provided by Brendan Curti, M.D., oncologist and prostate cancer researcher, Providence Cancer Center.
Many different systemic therapies have been tested for melanoma over the past 50 years, with generally disappointing results. The phase 3 study of ipilimumab was the first to show a survival benefit for any medical therapy in melanoma. – By Brendan Curti, M.D., medical director, Providence Biotherapy Program, Providence Melanoma Program
A study at Providence Cancer Center builds on the success of sorafenib. – By Todd S. Crocenzi, medical oncologist and researcher
Two of Providence Cancer Center’s top researchers were invited to China in October to talk about advances in immunotherapy, while others spoke in Italy and Chile. Here’s a partial list of our specialists’ appearances and publications.
Recent trials have brought some consistency back to integrating EGFR antagonists in the treatment of metastatic colorectal cancer. – By Todd S. Crocenzi, M.D., medical oncologist and researcher
We’re transitioning from single gene mutation testing to mapping and decoding whole genomes – a leap forward in treatment planning. – Carlo Bifulco, M.D, pathologist
Recommended Resources